openPR Logo
Press release

Alzheimer's Disease FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight

02-04-2025 11:10 PM CET | Health & Medicine

Press release from: ABNewswire

Alzheimer's Disease FDA Approvals, Clinical Trials, Emerging

DelveInsight's, "Alzheimer's Disease Pipeline Insight" report provides comprehensive insights about 110+ companies and 120+ pipeline drugs in Alzheimer's-disease pipeline landscape. It covers the Alzheimer's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Alzheimer's Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Alzheimer's Disease Treatment Landscape. Click here to read more @ Alzheimer's Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Alzheimer's Disease Pipeline Report

* In January 2025:- Novo Nordisk- The study is being conducted to understand how the medicine, semaglutide, affects the immune system and other biological processes in people with Alzheimer's disease. Semaglutide is a medicine that doctors can prescribe in some countries for the treatment of type 2 diabetes and excess body weight.
* In January 2025:- Hoffmann-La Roche:- The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to moderate Alzheimer's disease (AD), who are amyloid positive based on amyloid positron emission tomography (PET) scan.
* In January 2025:- Bigespas Ltd:- Multicenter Randomized Double-blind Placebo-controlled Three-arm Parallel-group Clinical Study to Evaluate the Efficacy and Safety of DMB-I in the Treatment of Dementia Associated With Alzheimer's Disease. The purpose of this study is to assess the efficacy and safety of DMB-I for the treatment of patients with Alzheimer type dementia.
* In January 2025:- Eisai Inc.:- The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).
* DelveInsight's Alzheimer's Disease pipeline report depicts a robust space with 110+ active players working to develop 120+ pipeline therapies for Alzheimer's Disease treatment.
* The leading Alzheimer's Disease Companies such as AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Cassava Sciences, BioVie Inc., Novo Nordisk, Alector Inc., Longeveron Inc., TrueBinding, Inc., VT BIO, Luye Pharma Group Ltd., Lexeo Therapeutics, Merck Sharp & Dohme LLC, Regeneration Biomedical, Alnylam Pharmaceuticals, Sinotau Pharmaceutical Group, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd and others.
* Promising Alzheimer's Disease Therapies such as Aricept, INM-176, SAR110894, Donepezil, CPC-201, ENA713, Remternetug , and others.

Stay informed about the cutting-edge advancements in Alzheimer's Disease treatments. Download for updates and be a part of the revolution in care @ Alzheimer's Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Alzheimer's Disease Emerging Drugs Profile

* AR1001: AriBio Co., Ltd.

AR1001 is a selective inhibitor of phosphodiesterase 5. This new pyrrolo-pyrimidinone was first developed for treatment of erectile dysfunction in South Korea, and is now being tested for Alzheimer's Disease. Its maker claims AR1001 to be 10-fold more potent at inhibiting PDE5, and better at entering the brain, than approved PDE5 inhibitors, including sildenafil.

* NE3107: BioVie

NE3107 is an orally available small molecule with potential anti-inflammatory and insulin-sensitizing properties that can cross the blood-brain barrier. It was originally developed by NeurMedix and acquired by BioVie in April. The experimental molecule works by blocking the activation of two major regulators of inflammatory pathways: extracellular signal regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-B).

* LY3372689: Eli Lilly & Co.

LY3372689 is an orally active O-GlcNAcase (OGA) enzyme inhibitor. O-GlcNAcylation, i.e., addition of N-acetylglucosamine to serine and threonine residues, is a post-translational modification that regulates the function of many proteins. In particular, N-GlcNAcylation of tau reduces its propensity to form toxic aggregates. OGA catalyzes removal of O-GlcNAc. OGA inhibitors promote tau glycosylation, prevent aggregation, and appear to stabilize tau in a soluble, nonpathogenic form. LY3372689 can be used for tauopathies research, including Alzheimer's disease. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Alzheimer's disease.

* CT1812: Cognition Therapeutics

Cognition Therapeutics isdeveloping CT1812, an oral, brain-penetrant, small molecule therapeutic, which has been shown to protect neurons and synapses by preventing the binding of toxic oligomers. CT1812 acts as a neuroprotective agent both by shielding neurons and synapses from oligomer binding and by preventing oligomers from attaching to synapses in the first place. CT1812 may help mitigate the neurotoxic effects, slowing cognitive decline and progression of Alzheimer's disease. Currently, the drug is in the Phase II stage of development to treat Alzheimer's-disease.

* ABBV-916: AbbVie Inc.

ABBV-916 anti-ApE3 (N-terminal truncated, pyroglutamate-modified at amino acid position 3, amyloid beta) is a monoclonal antibody being investigated for the treatment of Alzheimer's Disease. The drug candidate is administered through intravenous route as an infusion. Currently, the drug is in the Phase II stage of development to treat Alzheimer's-disease.

* ALX-001: Allyx Therapeutics, Inc.

ALX-001 (previously BMS-984923) is a silent allosteric modulator of mGluR5, a first-in-class compound that selectively blocks the pathogenic activation of the receptor while preserving the physiological glutamate signaling that is required for normal cognition. ALX-001 has a wide therapeutic window that can saturate receptor binding while avoiding on-target toxicity observed with negative allosteric modulators. Currently, the drug is in the Phase I stage of development to treat Alzheimer's disease.

Learn more about Alzheimer's Disease Drugs opportunities in our groundbreaking Alzheimer's Disease research and development projects @ Alzheimer's Disease Unmet Needs [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Alzheimer's Disease Companies

AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Cassava Sciences, BioVie Inc., Novo Nordisk, Alector Inc., Longeveron Inc., TrueBinding, Inc., VT BIO, Luye Pharma Group Ltd., Lexeo Therapeutics, Merck Sharp & Dohme LLC, Regeneration Biomedical, Alnylam Pharmaceuticals, Sinotau Pharmaceutical Group, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd and others.

Alzheimer's-disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Alzheimer's Disease Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Discover the latest advancements in Alzheimer's Disease treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Alzheimer's Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Alzheimer's Disease Pipeline Report

* Coverage- Global
* Alzheimer's Disease Companies- AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Cassava Sciences, BioVie Inc., Novo Nordisk, Alector Inc., Longeveron Inc., TrueBinding, Inc., VT BIO, Luye Pharma Group Ltd., Lexeo Therapeutics, Merck Sharp & Dohme LLC, Regeneration Biomedical, Alnylam Pharmaceuticals, Sinotau Pharmaceutical Group, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd and others.
* Alzheimer's Disease Therapies- Aricept, INM-176, SAR110894, Donepezil, CPC-201, ENA713, Remternetug, and others.
* Alzheimer's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Alzheimer's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Alzheimer's Disease Pipeline on our website @ Alzheimer's Disease Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Alzheimer's-disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Alzheimer's-disease- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* AR1001: AriBio Co., Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* LY3372689: Eli Lilly & Co.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ALX-001: Allyx Therapeutics, Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Alzheimer's-disease Key Companies
* Alzheimer's-disease Key Products
* Alzheimer's-disease- Unmet Needs
* Alzheimer's-disease- Market Drivers and Barriers
* Alzheimer's-disease- Future Perspectives and Conclusion
* Alzheimer's-disease Analyst Views
* Alzheimer's-disease Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alzheimers-disease-fda-approvals-clinical-trials-emerging-drugs-pipeline-insights-and-companies-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/knee-reconstruction-devices-market



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alzheimer's Disease FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight here

News-ID: 3849930 • Views:

More Releases from ABNewswire

Medicus Pharma (Nasdaq: MDCX) Bringing Scar-Free, Outpatient Treatment to an $8 Billion Cancer Market
Medicus Pharma (Nasdaq: MDCX) Bringing Scar-Free, Outpatient Treatment to an $8 …
Every year, millions of patients face cancer treatments that leave more scars than solutions. Basal cell carcinoma, prostate cancer, and acute urinary retention each carry not only physical burdens but staggering financial and emotional costs. Hospitals are overextended. Insurers are under pressure. Patients endure painful procedures, slow recoveries, and therapies that often fail to improve outcomes. The problem is not a lack of ambition in oncology. The problem is proof. Medicus
Worldle Goes Gaeilge: Global Hit Game Adds Irish Language, Announced at NEXUS Irish Games Conference
Worldle Goes Gaeilge: Global Hit Game Adds Irish Language, Announced at NEXUS Ir …
DUBLIN, Ireland - Oct 2, 2025 - Today at the NEXUS Irish Games Industry Conference, Games publisher Teuteuf Games announced a significant update for its viral geography game, Worldle: the addition of the Irish language (Gaeilge). The update, which goes live today, makes Irish the 12th language supported in the daily puzzle game that has captivated millions across the globe. Launched three years ago, Worldle has become a global phenomenon. The
Avanti Rides Debuts in Southern Florida, Transforming How Drivers and Passengers Connect
Avanti Rides Debuts in Southern Florida, Transforming How Drivers and Passengers …
Miami, FL - Avanti Rides introduces a new chapter in ride-hailing by combining passenger safety, driver empowerment, and seamless technology into a single app. Designed for the evolving needs of both drivers and riders, Avanti is delivering smarter bookings, stronger protection, and unmatched flexibility. Built for Drivers Who Want More Than Just Rides Avanti Rides recognizes that drivers are the foundation of the platform and offers a range of benefits focused on
UVS-IT Unveils Guide to Choosing the Best Managed IT Services in Atlanta
UVS-IT Unveils Guide to Choosing the Best Managed IT Services in Atlanta
Hey there, Atlanta business warriors! Have you ever felt that picking the perfect Managed IT Service is a bit like choosing the ultimate wingman for your company's tech needs? Trust me, it's not just a matter of finding someone who looks good on paper. With technology increasingly steering the ship of our businesses, selecting a reliable Managed IT Service is becoming as crucial as that morning cup of coffee we

All 5 Releases


More Releases for Alzheimer

Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion. Data Bridge
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports. Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as